Avidity plans to submit for FDA Accelerated Approval for Duchenne exon 44 skipping at the end of 2025;  Open-label extension trial is still recruiting

Amenable to skipping exon 44

Avidity Biosciences, which received early funding from CureDuchenne, plans to submit for US FDA Accelerated Approval at the end of 2025 for Delpacibart zotadirsen (del-zota), an exon-skipping experimental therapeutic for individuals with Duchenne amenable to skipping exon 44.  Topline data from their EXPLORE44 trial will be released in Q1 of this year.   Topline data from the ongoing EXPLORE44 Open Label Extension, which is still recruiting, is expected in Q4 2025. 

Link to clinical trial: https://clinicaltrials.gov/study/NCT06244082

Link to press release: https://aviditybiosciences.investorroom.com/2025-01-08-Avidity-Biosciences-Plans-First-BLA-Submission-and-Accelerates-Commercialization-Preparations-for-Three-Rare-Muscle-Disease-Programs-in-2025

Related Posts

Share This Page

Make an Impact

You can advance the care, treatment and cure for Duchenne muscular dystrophy. Contributions in any amount can truly make a difference and can be credited to a fundraiser or event from the list below.

Donate